Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Represents India-Based Healthcare Company In Drug Portfolio Acquisition

January 30, 2017

WASHINGTONCovington represented India-based Piramal Enterprises and its wholly owned Critical Care subsidiary in the UK in its agreement to acquire a portfolio of intrathecal spasticity and pain management drugs from Mallinckrodt LLC. 

The purchase price was $171 million, plus an earn-out of up to an additional $32 million. This is the third acquisition that Covington has led for Piramal over the past six months.

The Covington team included Ralph Voltmer and Brian Yang (corporate); Jim O’Connell, Megan Gerking and Habin Chung (antitrust); Michael Francese and Victoria Ha (employee benefits);  Peter Safir and Christina Kuhn (food & drug regulatory); Stefanie Doebler (health care compliance); Adrian Perry and David Wildman (intellectual property); Sara Needles (life sciences); and Rob Heller and John Oldak (tax).

Share this article: